IL277174B1 - Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodies - Google Patents

Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodies

Info

Publication number
IL277174B1
IL277174B1 IL277174A IL27717420A IL277174B1 IL 277174 B1 IL277174 B1 IL 277174B1 IL 277174 A IL277174 A IL 277174A IL 27717420 A IL27717420 A IL 27717420A IL 277174 B1 IL277174 B1 IL 277174B1
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
agonist
cdr
Prior art date
Application number
IL277174A
Other languages
Hebrew (he)
Other versions
IL277174B2 (en
IL277174A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL277174A publication Critical patent/IL277174A/en
Publication of IL277174B1 publication Critical patent/IL277174B1/en
Publication of IL277174B2 publication Critical patent/IL277174B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

- 135 - 277174/ CLAIMS
1. A 4-1BB (CD137) agonist for use in a method for treating a B-cell proliferative disorder, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody selected from rituximab or obinutuzumab, wherein: (a) said B-cell proliferative disorder is selected from the group consisting of Non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), marginal zone lymphoma (MZL), Multiple myeloma (MM) and Hodgkin lymphoma (HL); and (b) said 4-1BB agonist is an antigen binding molecule comprising (i) one antigen binding domain capable of specific binding to CD19, (ii) a first and a second polypeptide that are linked to each other by a disulfide bond, and (iii) an IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and P329G (EU numbering); and (c) said first polypeptide comprises two ectodomains of 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7 and SEQ ID NO:8 that are connected to each other by a peptide linker and said second polypeptide comprises one ectodomain of 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7 and SEQ ID NO:8.
2. The 4-1BB agonist for use in a method of claim 1, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition or administered separately in two different compositions.
3. The 4-1BB agonist for use in a method of claims 1 or 2, wherein the ectodomains of 4-1BBL comprise the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:5.
4. The 4-1BB agonist for use in a method of any one of claims 1 to 3, wherein the antigen binding domain capable of specific binding to CD19 comprises (a) a heavy chain variable region (VHCD19) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:11, and a light chain variable region (VLCD19) comprising (iv) CDR-L1 comprising the amino acid - 136 - 277174/ sequence of SEQ ID NO:12, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:13, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:14, or (b) a heavy chain variable region (VHCD19) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:15, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:16, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:17, and a light chain variable region (VLCD19) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:18, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:19, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:20.
5. The 4-1BB agonist for use in a method of any one of claims 1 to 4, wherein the antigen binding domain capable of specific binding to CD19 comprises a heavy chain variable region (VHCD19) comprising an amino acid sequence of SEQ ID NO:21 and a light chain variable region (VLCD19) comprising an amino acid sequence of SEQ ID NO:22 or wherein the antigen binding domain capable of specific binding to CD19 comprises a heavy chain variable region (VHCD19) comprising an amino acid sequence of SEQ ID NO:23 and a light chain variable region (VLCD19) comprising an amino acid sequence of SEQ ID NO:24.
6. The 4-1BB agonist for use in a method of any one of claims 1 to 5, wherein (a) the antigen binding domain capable of specific binding to CD19 is a Fab, and (b) said first polypeptide as defined in claim 1b(ii) comprises the amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.
7. The 4-1BB agonist for use in a method of any one of claims 1 to 6, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41 and a second light chain comprising the amino acid sequence of SEQ ID NO:42.
8. The 4-1BB agonist for use in a method of any one of claims 1 to 7, wherein the combination is administered concomitant at intervals from about one week to three weeks.
9. The 4-1BB agonist for use in a method of any one of claims 1 to 8, wherein a pretreatment with an Type II anti-CD20 antibody, preferably obinutuzumab, is performed prior to the combination treatment, wherein the period of time between the pretreatment and the combination treatment is sufficient for the reduction of B-cells in the individual in response to the Type II anti-CD20 antibody, preferably obinutuzumab.
10. A pharmaceutical composition comprising - 137 - 277174/ - a 4-1BB agonist as defined in claim 1, and - an anti-CD20 antibody selected from rituximab or obinutuzumab, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition.
11. The pharmaceutical composition of claim 10 for use as medicament.
12. The pharmaceutical composition of claims 10 or 11 for use in the treatment of a B-cell proliferative disorder selected from the group consisting of Non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), marginal zone lymphoma (MZL), Multiple myeloma (MM) and Hodgkin lymphoma (HL).
13. The pharmaceutical composition of any one of claims 10 to 12, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:and a second light chain comprising the amino acid sequence of SEQ ID NO:42.
IL277174A 2018-03-13 2019-03-11 Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodies IL277174B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161435 2018-03-13
PCT/EP2019/055946 WO2019175071A1 (en) 2018-03-13 2019-03-11 Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies

Publications (3)

Publication Number Publication Date
IL277174A IL277174A (en) 2020-10-29
IL277174B1 true IL277174B1 (en) 2025-08-01
IL277174B2 IL277174B2 (en) 2025-12-01

Family

ID=61691234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277174A IL277174B2 (en) 2018-03-13 2019-03-11 Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodies

Country Status (14)

Country Link
US (1) US20210163617A1 (en)
EP (1) EP3765489B1 (en)
JP (1) JP7159332B2 (en)
KR (1) KR102836393B1 (en)
CN (2) CN119074915A (en)
AU (1) AU2019236372B2 (en)
BR (1) BR112020015568A2 (en)
CA (1) CA3092002A1 (en)
ES (1) ES2998140T3 (en)
IL (1) IL277174B2 (en)
MX (1) MX2020009468A (en)
PL (1) PL3765489T3 (en)
TW (1) TWI828662B (en)
WO (1) WO2019175071A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788979T3 (en) 2014-11-14 2020-10-23 Hoffmann La Roche Antigen-binding molecules comprising a ligand trimer of the TNF family
JP6996979B2 (en) 2015-03-31 2022-02-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Antigen-binding molecule containing trimer TNF family ligand
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
JP7125400B2 (en) 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with targeted 4-1BB (CD137) agonists
KR102692708B1 (en) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
CA3047070A1 (en) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110402255B (en) 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 A novel bispecific antigen-binding molecule capable of specifically binding CD40 and FAP
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
TWI841551B (en) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1bb (cd137) agonists
CR20200459A (en) 2018-04-13 2020-11-11 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
US11242396B2 (en) 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
CR20210326A (en) 2018-12-21 2021-09-10 Hoffmann La Roche CD28 ANTIGEN BINDING AGONIST MOLECULES ACTING ON THE TUMOR
AR121706A1 (en) 2020-04-01 2022-06-29 Hoffmann La Roche OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
CR20220637A (en) 2020-06-19 2023-01-31 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND CD19
CN115197329A (en) * 2021-04-13 2022-10-18 晶源生物医药(苏州)有限公司 4-1BB agonist and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075278A1 (en) * 2014-11-14 2016-05-19 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808353C2 (en) 1977-04-18 1984-01-19 Hitachi Metals, Ltd., Tokyo Earring
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Modifications of or for denatured antibodies
FI903489A7 (en) 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (en) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 How to regulate transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT2857516T (en) 2000-04-11 2017-08-28 Genentech Inc Multivalent antibodies and uses therefor
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
PL213948B1 (en) 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR100944575B1 (en) 2002-10-17 2010-02-25 젠맵 에이/에스 Human monoclonal antibodies against CD20
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
HUE038955T2 (en) 2003-11-05 2018-12-28 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
DK1691833T3 (en) 2003-11-28 2010-05-03 Micromet Ag Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CN1961003B (en) 2004-03-31 2013-03-27 健泰科生物技术公司 Humanized anti-TGF-beta antibodies
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (en) 2004-09-23 2018-07-23 Genentech Inc Cysteine modified antibodies and conjugates.
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
PL2604693T3 (en) 2008-07-21 2016-09-30 TNFSF single chain molecules
PE20171512A1 (en) 2010-08-13 2017-10-20 Roche Glycart Ag ANTI-FAP ANTIBODIES
LT2691417T (en) 2011-03-29 2018-10-25 Roche Glycart Ag Antibody fc variants
KR102069397B1 (en) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Fc-receptor based affinity chromatography
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
WO2015179236A1 (en) * 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
PL3177643T3 (en) * 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
JP6996979B2 (en) * 2015-03-31 2022-02-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Antigen-binding molecule containing trimer TNF family ligand
AU2016335842A1 (en) * 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
EP3231813A1 (en) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2018017649A1 (en) * 2016-07-19 2018-01-25 Unum Therapeutics Inc. Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment
KR102692708B1 (en) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075278A1 (en) * 2014-11-14 2016-05-19 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOHRT, HOLBROOK E., ET AL., IMMUNOMODULATION OF NK CELLS THROUGH 4-1BB (CD137) TO IMPROVE THE ANTI-LYMPHOMA ACTIVITY OF RITUXIMAB: ANTIBODY-BASED ANTI-LYMPHOMA SYNERGY., 31 December 2010 (2010-12-31) *
LIU R. ET AL.,, EFFICIENT INHIBITION OF HUMAN B-CELL LYMPHOMA IN SCID MICE BY SYNERGISTIC ANTITUMOR EFFECT OF HUMAN 4-1BB LIGAND/ANTI-CD20 FUSION PROTEIN AND ANTI-CD3/ANTI-CD20 DIABODIES., 30 June 2010 (2010-06-30) *

Also Published As

Publication number Publication date
US20210163617A1 (en) 2021-06-03
TWI828662B (en) 2024-01-11
CA3092002A1 (en) 2019-09-19
ES2998140T3 (en) 2025-02-19
KR102836393B1 (en) 2025-07-22
AU2019236372A1 (en) 2020-07-30
JP2021515782A (en) 2021-06-24
KR20200132913A (en) 2020-11-25
TW202003552A (en) 2020-01-16
EP3765489B1 (en) 2024-10-16
IL277174B2 (en) 2025-12-01
IL277174A (en) 2020-10-29
EP3765489C0 (en) 2024-10-16
CN119074915A (en) 2024-12-06
CN111683961A (en) 2020-09-18
EP3765489A1 (en) 2021-01-20
PL3765489T3 (en) 2025-02-10
JP7159332B2 (en) 2022-10-24
BR112020015568A2 (en) 2020-12-29
MX2020009468A (en) 2020-10-22
AU2019236372B2 (en) 2024-06-20
WO2019175071A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
JP2020504723A5 (en)
US12600779B2 (en) LAG-3-binding molecules and methods of use thereof
JP7551693B2 (en) Variable region of NKp46 binding protein
US20230357404A1 (en) Pd-1-binding molecules and methods of use thereof
US12331119B2 (en) Modified Fc fragment, antibody comprising same, and application thereof
RU2018126297A (en) ANTIBODIES AIMED AT CD32B AND WAYS TO USE THEM
JP2022507295A5 (en)
CA3089230A1 (en) Trispecific antigen binding proteins
JP2021524478A5 (en)
JP2022515258A5 (en)
JP2023547506A5 (en)
AU2021411581A9 (en) Antibodies to tnfr2 and uses thereof
JP2025508317A5 (en)
CA3136255A1 (en) Dosing regimens of bispecific cd123 x cd3 diabodies in the treatment of hematologic malignancies
FI3681911T3 (en) Binding proteins to the human thrombin receptor, par4
JP7192042B2 (en) LAG-3 binding molecules and methods of use thereof
CA2986953C (en) Lag-3-binding molecules and methods of use thereof
NZ778352A (en) Tumor-targeted agonistic cd28 antigen binding molecules
NZ778352B2 (en) Tumor-targeted agonistic cd28 antigen binding molecules
RU2024119658A (en) AGONISTIC ANTIBODIES TO LTBR AND BISPECIFIC ANTIBODIES CONTAINING THEM
RU2021116831A (en) HUMANIZED ANTI-SIRPα ANTIBODIES
EA041483B1 (en) LAG-3 BINDING MOLECULES AND METHODS FOR THEIR APPLICATION
BR112017026330B1 (en) LAG-3 BINDING MOLECULE COMPRISING A LAG-3 BINDING DOMAIN CAPABLE OF BINDING BOTH HUMAN AND CYNOMOLGUS MONKEY LAG-3
RU2021112776A (en) HUMANIZED AND AFINITY MATURE ANTIBODIES AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION
NZ767672A (en) Antigen binding molecules comprising a tnf family ligand trimer